Wirote Lausoontornsiri

A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma

Thomas Yau, Riccardo Lencioni, Wattana Sukeepaisarnjaroen et al. · Clinical Cancer Research · 2016 · 74 citations · Full text

Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer

Stephen Johnston, Mark Basik, Roberto Hegg et al. · Breast Cancer Research and Treatment · 2016 · 49 citations

Breast Oncology, Phase Ii, Medicine +8

A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).

Thomas Cheung Yau, Wattana Sukeepaisarnjaroen, Yee Chao et al. · Journal of Clinical Oncology · 2012 · 26 citations

Phase I/ii Study, Pathology, Tumor Biology +17

Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).

Stephen Johnston, Mark Basik, Roberto Hegg et al. · Journal of Clinical Oncology · 2013 · 19 citations

Breast Oncology, Gynecology, Pharmacotherapy +17

Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand

P. Lerdkiattikorn, Usa Chaikledkaew, Wirote Lausoontornsiri et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2014 · 10 citations